CNBX Pharmaceuticals Inc.
Key Highlights
- CNBX Pharmaceuticals Inc. is categorized as a "smaller reporting company" and an "emerging growth company," reflecting its early growth stage.
- As of February 28, 2025, the company's public common stock had a market value of approximately $251,840, with shares priced at $0.0076 each.
- As of November 20, 2025, the company had 553,962,206 shares of common stock outstanding.
Financial Analysis
CNBX Pharmaceuticals Inc. Annual Report - How They Did This Year
This review covers CNBX Pharmaceuticals Inc.'s performance for the fiscal year that ended on August 31, 2025.
First off, it's helpful to know that CNBX Pharmaceuticals is classified as a "smaller reporting company" and an "emerging growth company." This means it's a relatively small company that's still in its early growth stages, which often comes with different opportunities and risks compared to larger, more established businesses.
Looking at the company's market value, as of February 28, 2025, the total value of its common stock held by public investors (not insiders) was approximately $251,840. This was based on a share price of $0.0076 per share. This indicates a very small market capitalization, often referred to as a 'micro-cap' or 'penny stock' company. As of November 20, 2025, there were 553,962,206 shares of common stock outstanding.
Key Takeaways:
- CNBX Pharmaceuticals Inc. is categorized as a "smaller reporting company" and an "emerging growth company," reflecting its early growth stage.
- As of February 28, 2025, the company's public common stock had a market value of approximately $251,840, with shares priced at $0.0076 each.
- As of November 20, 2025, the company had 553,962,206 shares of common stock outstanding.
Risk Factors
- The company's classification as a "smaller reporting company" and an "emerging growth company" implies different opportunities and risks compared to larger businesses.
- Its very small market capitalization, often referred to as a 'micro-cap' or 'penny stock' company, indicates higher inherent risk.
Why This Matters
This annual report is crucial for investors as it confirms CNBX Pharmaceuticals Inc.'s status as both a "smaller reporting company" and an "emerging growth company." These designations mean the company operates under reduced disclosure requirements compared to larger firms, which can limit the amount of public information available for due diligence. For investors, this implies a higher degree of inherent risk, but also the potential for significant growth if the company's early-stage ventures prove successful.
The reported market value of just $251,840 and a share price of $0.0076 firmly place CNBX in the micro-cap, or "penny stock," category. This valuation signals extreme speculation and volatility. Investors should be aware that such low-priced stocks are highly susceptible to price manipulation, have limited liquidity, and carry a substantial risk of capital loss. The large number of outstanding shares (over 553 million) at such a low price also suggests potential for significant dilution or a need for a reverse stock split in the future, which can be concerning for existing shareholders.
Financial Metrics
Learn More
About This Analysis
AI-powered summary derived from the original SEC filing.
Document Information
SEC Filing
View Original DocumentAnalysis Processed
December 23, 2025 at 03:50 AM
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.